Gennex Laboratories intimated a board meeting on May 30, 2026, to consider audited financial results for FY26.
The agenda includes adopting standalone and consolidated financial statements and reviewing the statutory auditor's reports.
The trading window for securities will reopen 48 hours after the declaration of the FY26 audited results.